Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune MicroenvironmentNicholas Denton, Timothy P. Cripe, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2018Cited by 56
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivityJennifer L. Leddon, Timothy P. Cripe, Mark A. Currier et al.|Molecular Therapy — Oncolytics|2014Cited by 44
Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in childrenTimothy P. Cripe, Gregory K. Friedman, Chun‐Yu Chen et al.|Molecular Therapy — Oncolytics|2015Cited by 22
Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in childrenGregory K. Friedman, Timothy P. Cripe, Elizabeth A. Beierle et al.|Molecular Therapy — Oncolytics|2015Cited by 13
518. Tumor Associated Macrophages Mitigate Oncolytic Herpes Simplex Virus Efficacy in Part Through TGF-β SignalingNicholas Denton, Timothy P. Cripe, Chun‐Yu Chen et al.|Molecular Therapy|2016Cited by 1